Chinook Therapeutics U.S., Inc. — Form D
Chinook Therapeutics U.S., Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2019-08-29. The offering totals $65.0M, of which $65.0M was reported sold. Industry: Other Technology.
Offering
- Filed: 2019-08-29
- Form: D
- Accession: 0001768185-19-000005
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $65.0M
- Amount sold: $65.0M
- Investors: 5
- Date of first sale: 2019-02-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-347663
Issuer
- Name: Chinook Therapeutics U.S., Inc.
- CIK: 0001768185
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 1600 FAIRVIEW AVE. E., SEATTLE, WA, 98102
- Phone: 206-485-7051
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Srini Akkaraju | Director | Agoura Hills, CA |
| Sam Hall | Director | Seattle, WA |
| Srinivas Akkaraju | Director | Palo Alto, CA |
| Jerel Davis | Director | Alameda, CA |
| Paul Eisenberg | Director | New York, NY |
| Jeremy Caldwell | Director | Seattle, WA |
| Andrew King | Executive Officer | Seattle, WA |
| Tom Frolich | Executive Officer | Seattle, WA |
| Preston Klassen | Director | Seattle, WA |
| Eric Dobmeier | Director | Seattle, WA |
| Eric Dobmeier | Executive Officer | Seattle, WA |
| Alan Glicklich | Executive Officer | Seattle, WA |
Other filings by this issuer (1)
More